The groups treated with B16-GM+B7.2/80 and B16-GM+B7.2/80 + 3LL, contributing double dose of cell antigen, GM-CSF and B7.2, surprisingly only reached about 60% tumor growth inhibition. This evidence concerns the gene CD86 and neoplasm.